Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: inflammation and immune disorder therapeutics - Asterand

Drug Profile

Research programme: inflammation and immune disorder therapeutics - Asterand

Alternative Names: R99 programme - Asterand

Latest Information Update: 13 Feb 2007

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Asterand plc
  • Class Small molecules
  • Mechanism of Action Dinoprostone agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Immunological disorders; Inflammation

Most Recent Events

  • 13 Feb 2007 Discontinued - Preclinical for Immunological disorders in United Kingdom (unspecified route)
  • 13 Feb 2007 Discontinued - Preclinical for Inflammation in United Kingdom (unspecified route)
  • 30 Jan 2006 Pharmagene has merged with Asterand to form Asterand plc
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top